Biomx Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.35
- Today's High:
- $0.4075
- Open Price:
- $0.3849
- 52W Low:
- $0.132
- 52W High:
- $0.69
- Prev. Close:
- $0.385
- Volume:
- 29377
Company Statistics
- Market Cap.:
- $17.47 million
- Book Value:
- 0.345
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -30.6%
- Return on Equity TTM:
- -104.67%
Company Profile
Biomx Inc had its IPO on 2019-03-13 under the ticker symbol PHGE.
The company operates in the Healthcare sector and Biotechnology industry. Biomx Inc has a staff strength of 54 employees.
Stock update
Shares of Biomx Inc opened at $0.38 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.35 - $0.41, and closed at $0.39.
This is a +0.78% increase from the previous day's closing price.
A total volume of 29,377 shares were traded at the close of the day’s session.
In the last one week, shares of Biomx Inc have increased by +2.11%.
Biomx Inc's Key Ratios
Biomx Inc has a market cap of $17.47 million, indicating a price to book ratio of 0.1796 and a price to sales ratio of 0.
In the last 12-months Biomx Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-24216000. The EBITDA ratio measures Biomx Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Biomx Inc’s operating margin was 0% while its return on assets stood at -30.6% with a return of equity of -104.67%.
In Q2, Biomx Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Biomx Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Biomx Inc’s profitability.
Biomx Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.5858. Its price to sales ratio in the trailing 12-months stood at 0.
Biomx Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $41.25 million
- Total Liabilities
- $11.67 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $1000
- Dividend Payout Ratio
- 0%
Biomx Inc ended 2024 with $41.25 million in total assets and $0 in total liabilities. Its intangible assets were valued at $41.25 million while shareholder equity stood at $15.87 million.
Biomx Inc ended 2024 with $0 in deferred long-term liabilities, $11.67 million in other current liabilities, 3000.00 in common stock, $-149573000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $29.71 million and cash and short-term investments were $29.71 million. The company’s total short-term debt was $6,045,000 while long-term debt stood at $8.16 million.
Biomx Inc’s total current assets stands at $33.19 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $657000.00 compared to accounts payable of $2.23 million and inventory worth $294000.00.
In 2024, Biomx Inc's operating cash flow was $0 while its capital expenditure stood at $1000.
Comparatively, Biomx Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.39
- 52-Week High
- $0.69
- 52-Week Low
- $0.132
- Analyst Target Price
- $
Biomx Inc stock is currently trading at $0.39 per share. It touched a 52-week high of $0.69 and a 52-week low of $0.69. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.4 and 200-day moving average was $0.33 The short ratio stood at 0.07 indicating a short percent outstanding of 0%.
Around 2034.2% of the company’s stock are held by insiders while 1679.5% are held by institutions.
Frequently Asked Questions About Biomx Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company’s pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.